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Abstract
Background:  Patients with advanced gallbladder and biliary tract carcinoma face a dismal
prognosis, as no effective palliative chemotherapy exists. The antitumor effect of gemcitabine is
schedule-dependent rather than dose-dependent. We evaluated the activity of a prolonged infusion
of gemcitabine in advanced gallbladder and biliary tract carcinomas.
Methods: Nineteen consecutive eligible patients were enrolled. All patients were required to have
histologically confirmed diagnosis and measurable disease. Gemcitabine was infused over 24 hours
at a dose of 100 mg/m2 on days 1, 8, and 15. Treatment was repeated every 28 days until
progression of disease or limiting toxicity. Tumor response was evaluated every second course by
computed tomography (CT) scans.
Results: Eighteen patients were evaluable for response. A total of 89 cycles of therapy were
administered. One partial response was observed (6%; 95% confidence interval (CI): 0–27%) and
ten additional patients had stable disease for at least two months (disease control rate 61%; 95%
CI: 36–83%). The therapy was well tolerated, with moderate myelosuppression as the main
toxicity. The median time to tumor progression and median overall survival was 3.6 months (95%
CI 2.6–4.6 months) and 7.5 months (95% CI 6.5–8.5 months), respectively.
Conclusion: Weekly 24-hour gemcitabine at a dose of 100 mg/m2 is well tolerated. There was a
relatively high rate of disease control for a median duration of 5.3 months (range 2.8–18.8 months).
However, the objective response rate of this regimen in gallbladder and biliary tract carcinomas
was limited.
Background
Adenocarcinomas of the gallbladder and the biliary tract
are relatively uncommon in the western world, with
approximately 5,000 cases of gallbladder carcinoma and
2,500 cases of cholangiocarcinoma annually in the USA
[1,2]. Worldwide, the highest prevalence of gallbladder
cancer is seen in Israel, Mexico, Chile, Japan, and among
Native American women, particularly those living in New
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Mexico. Incidence of cholangiocarcinoma is highest in
Israel, Japan, among Native Americans, and in Southeast
Asia, where it can reach 87 per 100,000 [3].
Biliary tract tumors can occur anywhere in the hepatobil-
iary system. Cholangiocarcinoma may be further classi-
fied as intrahepatic or extrahepatic (hilar and distal bile
duct) carcinomas. Hilar tumors, so called Klatskin's
tumors, usually require partial liver resection for cure,
whereas distal tumors may require pancreatectomy.
Gallbladder carcinoma has been linked to several risk fac-
tors. Gallstones, especially larger than 3 cm, chronic
inflammation, bacterial infection, polyps, calcified (por-
celain) gallbladder, ulcerative colitis, high energy and
total carbohydrate intake, and high body mass index in
women increase risk. Risk factors for cholangiocarcinoma
are well understood, although most patients lack identifi-
able risks. Patients with primary sclerosing cholangitis,
congenital choledochal cysts (most likely due to associ-
ated inflammation and bacterial infection), ulcerative col-
itis, exposure to carcinogens including cigarette smoke,
hepatolithiasis, liver infection, hepatitis C, and biliary
parasites carry an elevated risk [3].
Due to the lack of characteristic early symptoms, a defini-
tive diagnosis of gallbladder and biliary tract carcinoma is
often established at an advanced stage, and prognosis of
patients with advanced tumors remains dismal. Even in
patients undergoing aggressive surgery, the general out-
come has been disappointing. Five-year survival rates are
between 5–10% [1]. Median survival of patients with
advanced-stage disease is in the range of only a few
months. Due to the lack of randomized phase III studies
there is no standard regimen for palliative chemotherapy
of gallbladder and biliary tract carcinomas. Depending on
the patient's general condition best supportive care, a clin-
ical trial, 5-FU, or gemcitabine is recommended according
to guidelines of the National Comprehensive Cancer
Network.
Gemcitabine is phosphorylated by deoxycytidine kinase
into the active metabolite gemcitabine triphosphate
(GemTP). The rate-limiting step in the formation of
GemTP is the phosphorylation of gemcitabine to the
monophosphate by deoxycytidine kinase [4]. The diphos-
phate is a potent inhibitor of ribonucleotide reductase, an
action that reduces deoxynucleotide pools. Decreased cel-
lular concentrations of deoxycytidine triphosphates per-
mit a more rapid phosphorylation of gemcitabine and
decrease the metabolic clearance of gemcitabine nucle-
otides. As a consequence of this, the active nucleotide
forms of gemcitabine are effectively accumulated to high
concentrations in the cell [5].
According to the rate-limited activation of gemcitabine a
schedule-dependent antitumor effect of gemcitabine was
found in various in vivo model systems in preclinical
studies [6] suggesting slower infusion rates in the clinical
setting. Furthermore, the treatment of mice bearing the
colon 26–10 murine colon carcinoma was considerably
more effective by applying a weekly 24-hour schedule [7].
Based on the results of a pilot study [8] and a phase II
study in patients with pancreatic adenocarcinoma [9] we
started a phase II trial of weekly 24-hour infusion of gem-
citabine in patients with advanced gallbladder and biliary
tract carcinoma.
Methods
Patients
To be eligible for the trial, patients were required to have
histologically confirmed, irresectable or metastatic carci-
noma of the gallbladder or biliary tract. Patients had to
have measurable disease on a computed tomography
(CT) scan or magnetic resonance imaging (MRI) and had
to have a performance status (WHO) = 2 or less. Patients
were allowed to have received one previous chemother-
apy, but no previous treatment with gemcitabine. They
also met the following laboratory criteria: serum bilirubin
value ≤  two times upper normal limit, leukocyte count =
3.0 × 109/L or greater, platelet count = 100 × 109/L, and
serum creatinine = 2.0 mg/dL or less.
Patients with active infections, unstable cardiovascular
conditions, brain metastases, or other serious medical ill-
nesses were excluded from this trial.
Informed consent was obtained from all patients included
in the study, which was approved by local ethics
committees.
Treatment Plan
Therapy was administered on an outpatient basis and
patients were premedicated with appropriate antiemetics.
Patients received gemcitabine (100 mg/m2) as a 24-hour
intravenous (i.v.) infusion. Treatments were repeated
every week for three consecutive weeks followed by one
week of rest; a full cycle consisted of four weeks.
Doses were modified according to the following criteria:
The weekly gemcitabine dose was reduced by 25% for
patients whose leukocyte count was 2.5–3.0 × 109/mL,
whose platelet count was 75–100 × 109/L, or if grade 2
nonhematologic toxicity was present. The weekly dose
was reduced by 50% for patients whose leukocyte count
was 2.0–2.5 × 109/L or whose platelet platelet count was
50–75 × 109/L. The weekly dose was omitted if the leuko-
cyte count was less than 2.0 × 109/L, platelet count wasBMC Cancer 2005, 5:61 http://www.biomedcentral.com/1471-2407/5/61
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less than 50 × 109/L, or grade 3 nonhematologic toxicity
was present.
Patient Evaluation
Weekly blood counts were obtained to determine the level
of myelosuppression. Before each cycle a full clinical eval-
uation noting the performance status and a physical exam
were performed and a complete chemistry panel was
obtained. In addition, CA19-9 levels were measured every
eight weeks.
The antitumor response was evaluated every eight weeks
by CT or MRI, unless signs of progression were evident. In
terms of response RECIST criteria [10] were applied, since
in most cases of these tumors interpretation of bi-dimen-
sional measurements is complicated by associated inflam-
mation and/or necrosis, as well as anatomical structures
in the vicinity. Complete response was defined as the dis-
appearance of all signs and symptoms of disease. Partial
response was defined as a decrease of > 30 % of the sum
of the largest diameters of target (= measurable) lesions
without appearance of new lesions or progression of non-
target (= evaluable) lesions. To be assigned a status of
response, changes in tumor measurement were confirmed
by repeat assessment that was performed no less than 4
weeks after the criteria for response were first met. Stable
disease was defined as no sufficient shrinkage to qualify
for partial response or less than a 20% increase in the sum
of the largest diameters of target lesions without appear-
ance of new lesions or progression of non-target lesions.
Progressive disease was defined as a 20% increase in the
sum of the largest diameters of target lesions or as appear-
ance of new lesions or as progression of non-target
lesions.
The response was validated by radiologists independent
of the study.
Disease control was defined as the absence of tumor pro-
gression (i.e. complete and partial response and stable
disease) for at least two months.
Statistical Methods
The primary end point of this trial was objective response.
Secondary end points included progression free survival,
overall survival, and toxicity.
Simon's optimal two-stage design was used for calculation
of the sample size [11]. Early stopping rules were provided
to allow for study discontinuation in the event of lack of
efficacy. Sufficient responses (greater than 2 in 18 evalua-
ble patients) were required to trigger the second phase of
enrollment for another 17 for a maximum of 35 patients.
95% confidence interval was calculated by the method of
Clopper and Pearson. Correlations are nonparametric by
the method of Spearman. Progression free survival and
overall survival were calculated from the start of chemo-
therapy until progression, death or last follow-up by the
Kaplan-Meier method using SPSS, version 12.0 software.
Results
A total of 19 patients – eight men and eleven women –
were entered onto this trial. Their pre-treatment character-
istics are listed in Table 1. The median age was 63 years
(range 30–83 years, 14 patients younger than 75 years).
All patients had adenocarcinomas. There were three
patients with gallbladder carcinoma, all of whom were
women. Four patients (21%) had relapse of disease after
surgery with incomplete resections in two patients. Two
patients (11%) had been previously treated with a combi-
nation of cyclophosphamide, leucovorin, 24-hour fluor-
ouracil and tamoxifen [12]. All other patients were
chemotherapy-naïve. Seven patients (37%) required bil-
iary tract decompression by endoscopic or percutaneous
stenting because of obstructive jaundice before the start of
chemotherapy. Baseline CA19-9 levels were recorded in
17 patients and were elevated in 14 of them. One female
patient was not evaluable regarding response due to early
discontinuation of therapy because of withdrawal of
consent.
Toxicity
A total of 89 cycles were administered during the trial
(median 4 cycles; range 1–19 cycles). Overall, weekly 24-
hour gemcitabine was well tolerated (Table 2). No treat-
ment-related deaths occurred. Myelosuppression was the
major toxicity. Among all 19 patients grade 3/4 neutrope-
nia occurred in four patients (21%) with no episode of
febrile neutropenia. One patient developed grade 4
thrombocytopenia with epistaxis and needed a platelet
transfusion. No grade 4 and only one case of grade 3 non-
hematologic toxicity effects were noted. Nausea and eme-
sis, when present, usually were mild. Grade 3 mucositis
was present in one patient. Allergic urticaria following
gemcitabine infusion was seen in one patient, but was
manageable by antiallergic medication during the further
course.
Response and Survival
No complete response was observed. One of the 18 eval-
uable patients (6%; 95%CI: 0–27%) with a gallbladder
carcinoma had a partial response. Ten additional patients
had stable disease for a median duration of 5.3 months
(range 2.8–18.8 months) resulting in a disease control
rate of 61% (95%CI: 36–83%). Two of these patients had
gallbladder carcinoma, four intrahepatic cholangiocarci-
noma, and four extrahepatic cholangiocarcinoma. Seven
(39%, 95%CI: 17–64%) patients had stable disease after
4 cycles of chemotherapy.BMC Cancer 2005, 5:61 http://www.biomedcentral.com/1471-2407/5/61
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Median progression free survival was 3.6 months (95% CI
2.6–4.6 months) with a 3 and 6-month progression free
survival rate of 61% and 23%, respectively. Median over-
all survival for all 19 patients was 7.5 months (95% CI:
6.5–8.5 months) with a 6 and 12-month survival rate of
73% and 34%, respectively (Figure 1). There was a signif-
icant correlation between progression free and overall sur-
vival (r = 0.54, p = 0.016).
In fourteen of seventeen patients (82%) assessed baseline
CA19-9 levels were elevated (median 581, mean 98,849,
range 115–1,244,000; normal < 32 U/mL). In eleven
patients follow-up values were obtained. Ten of these
eleven patients had elevated baseline levels. There was a
significant negative correlation (r = -0.65, p = 0.032)
between relative changes of CA19-9 during chemotherapy
compared with baseline and progression free survival.
Discussion
In this phase II trial of a prolonged infusion of gemcitab-
ine for advanced gallbladder and biliary tract carcinoma
we only found a 6% objective response rate (95%CI: 0–
27%). According to the early stopping rules accrual was
terminated after enrollment of 19 patients, thereof 18
evaluable for response. Disease control for at least two
months was observed in 11 patients (61%, 95%CI: 36–
83%) for a median duration of 5.3 months (range 2.8–
18.8 months). As expected there was a significant correla-
tion of progression free and overall survival. Toxicity was
generally mild with myelosuppression as the major
toxicity.
Only relatively small phase II trials have assessed the effi-
cacy and toxicity profiles of chemotherapy regimens in the
palliative treatment of gallbladder cancer and cholangi-
Table 1: Patient characteristics of all patients enrolled.
Total no. of patients (evaluable for response) 19 (18)
Sex (female/male) 11/8
Age, median (range) 63 (30–
83)
Performance status (WHO)
01  ( 5 % )
11 2  ( 6 3 % )
2 6 (32%)
Tumor site
Gallbladder 3 (16%)
Intrahepatic bile ducts 9 (47%)
Extrahepatic bile ducts 7 (37%)
Site of metastasis
Liver 9 (47%)
Lung 2 (11%)
Lymph nodes 5 (26%)
Peritoneum 2 (11%)
Recurrence after previous surgical resection 4 (21%)
Pre-treatment requiring stent or percutaneous 
transhepatic drainage because of obstructive jaundice
7 (37%)
Pre-treatment chemistries
Total bilirubin (mg/dl)
Median 0,7
Range 0,3–2,3
Gamma-glutamyltransferase (<66 U/La)
Median 159
Range 34–671
Aspartate aminotransferase (10–50 U/la)
Median 29
Range 8–145
CA19-9 (<32 U/mLa)
Median 387
Range 4-1244000
a normal levels
Table 2: Treatment-related toxicities of all 19 patients enrolled.
Number of patients (%)
NCI-CTC Grade 1 2 3 4
Leukopenia 2 (11) 6 (32) 3 (16) 0
Neutropenia 3 (16) 1 (5) 2 (11) 2 (11)
Anemia 0 1 (5) 0 0
Thrombocytopenia 3 (16) 3 (16) 0 1 (5)
Diarrhea 1 (5) 1 (5) 0 0
Nausea/emesis 5 (26) 2 (11) 0 0
Stomatitis 3 (16) 2 (11) 1 (5) 0
NCI-CTC: National Cancer Institute Common Toxicity Criteria
Probability of progression free survival (dotted line) and  overall survival for all 19 patients enrolled Figure 1
Probability of progression free survival (dotted line) and 
overall survival for all 19 patients enrolled.BMC Cancer 2005, 5:61 http://www.biomedcentral.com/1471-2407/5/61
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ocarcinoma. Due to tumor-specific complications such as
obstructive jaundice with impaired hepatic metabolism
and biliary excretion toxicity profiles of chemotherapy
regimens may be different in gallbladder and biliary tract
carcinoma compared to other cancers. Single-agent and
multiagent regimens have yielded modest results in
patients with advanced biliary carcinomas. Overall
response rates and disease control rates are about 25%
(mostly 13–35%, range 0–64%) and about 65% (mostly
55–72%, range 19–94%), respectively [13].
Among several different new anticancer drugs, gemcitab-
ine has generated particular interest. Considered as stand-
ard treatment for advanced pancreatic carcinoma [14] and
given the histogenetic affinity between the pancreas and
the biliary tract, a number of phase II trials of gemcitabine
with differing results were conducted in patients with
advanced gallbladder and biliary tract cancers. Patients
mostly received gemcitabine at a dose of 1000 mg/m2 over
30 minutes.
Possible options to further improve the therapeutic effi-
cacy of gemcitabine monotherapy include modifications
of the administration schedule. Tempero et al. [15] found
improved activity of gemcitabine 1500 mg/m2 as a fixed
dose rate infusion of 10 mg/m2/min in comparison to
high dose gemcitabine (2200 mg/m2) infusion over 30
minutes in pancreatic cancer. Pharmacokinetic analysis in
this study also revealed significantly higher
concentrations of intracellular gemcitabine triphosphate
with the prolonged infusion. However, grade 3–4 hema-
tologic toxicity occurred in up to almost 50% in the fixed
dose rate arm. In contrast, in our trial of 24-hour gemcit-
abine at a dose of 100 mg/m2 toxicity was mild.
Median survival achieved by our patients was 7,5 months
(95% CI: 6.5–8.5) and therefore in the range of most
other studies investigating gemcitabine as single agent for
biliary tract cancer. Progression free survival (3.6 months;
95% CI 2.6–4.6) was similar to other published data of
phase II trials of gemcitabine in biliary tract cancer [Table
3]. Nevertheless, with only small objective response
observed our results do not support the use of gemcitab-
ine as continuous infusion in this setting.
Conclusion
In conclusion, weekly 24-hour infusion of gemcitabine at
a dose of 100 mg/m2 in patients with advanced gallblad-
der and biliary tract carcinoma can be safely administered
in an outpatient setting. A relatively high disease control
rate was observed in this trial. However, in terms of objec-
tive response antitumor activity was only marginal. There-
fore, gemcitabine as continuous infusion seems not to be
superior to gemcitabine administered in short term.
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